Le Lézard
Classified in: Health, Science and technology
Subject: Personnel

John Booth to Retire as CEO of Spineology Inc.


Spineology Inc. ("Spineology" or the "Company"), the leader in ultra-minimally invasive spine surgery, announced today that John Booth will retire from his role as Chief Executive Officer of Spineology, effective November 10, 2023. The Board of Directors has selected Brian Snider as its next Chief Executive Officer, effective November 13, 2023. Mr. Booth will remain with Spineology through 2024, serving in an advisory role to facilitate a smooth transition. Mr. Booth will also resign from the Board of Directors, and the Board has nominated Mr. Snider as a Director.

Snider joins Spineology with nearly twenty years of progressive leadership experience in the medical device industry. Most recently he served as Executive Vice President of Marketing for Alphatec Spine (NASDAQ: ATEC), as a member of the executive leadership team that was responsible for growing the company's market capitalization from $20M to over $1.2B. During his tenure with ATEC, he had accountability for a variety of disciplines in marketing and product development. Most recently, he was responsible for the Biologics, Cervical, and Thoracolumbar business units. Prior to ATEC, Snider spent nine years at NuVasive, Inc., a leader in innovative products and procedures for minimally disruptive spine surgery. During his tenure at NuVasive, Snider held senior level marketing positions in the Thoracolumbar business segment including the flagship procedure, XLIF®. Mr. Snider received his BBA in Marketing and Information Systems from George Washington University and his MBA from the Fuqua School of Business at Duke University.

"It has been a great privilege to work with a talented and passionate group of employees throughout the Company, who together have advanced the field of ultra-minimally invasive spine surgery significantly over the Company's history," said John Booth. "I have every confidence that the Company will continue to grow and provide disruptive solutions under Brian's leadership as the next CEO of Spineology."

Ed Spencer, Chairman of the Board of Spineology, expressed thanks for Booth's leadership. "On behalf of the Board of Directors, our employees, and Spineology's stockholders, I express my deep gratitude to John for his success in leading the Company, as well as for his service as a Spineology Board member for over 20 years."

"As we prepared for John's retirement, the Board unanimously agreed that Brian Snider was well suited to lead Spineology," continued Spencer. "His years of experience in growing evolutionary companies in the minimally invasive spine market will enable him to immediately contribute to Spineology's continued success."

"I am thrilled to join the Spineology team," said Snider. "Spineology is a company with a unique procedural foundation that is backed with strong clinical data. I am confident that we will deliver growth and surgical advancement during this next phase. I would like to thank the Board for the opportunity to serve the Spineology team, the shareholders, and most importantly, our patients."

About Spineology:

Spineology Inc. leads the way in ultra-minimally invasive spine surgery, revolutionizing how spine surgeons treat and heal back pain. Our proprietary Mesh technology sets us apart from traditional fusion procedures enabling surgeons to optimize outcomes while minimizing tissue disruption and enhancing patient recovery. With a strong commitment to patient-centered care and enabling disruptive technologies, Spineology continues to push the boundaries of what is possible in spine surgery today with the tools of tomorrow.


These press releases may also interest you

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...

at 11:55
The "Infectious Vaccine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...



News published on and distributed by: